A Landmark Laser Award Masks a Shrinking Organic Top Line, and the Reaffirmed Guide Spends Every Dollar of the Beat

Results vs. Consensus

Published consensus spans a narrow range: two providers carried $452M revenue and $0.22 adjusted EPS, a third carried $457.6M and $0.25. The beat is +5% to +6% on revenue across that range, and the EPS surprise is large in percentage terms only because the expected base was tiny. The adjusted EBITDA comparison and the FY27 EBITDA figure come from a single provider and are treated as indicative.

Year-over-year comparison

Sequential comparison

The sequential collapse is seasonal rather than a reversal. AV's fiscal first quarter is structurally its lightest and its fourth is its heaviest, and the FY26 pattern was identical in shape: $454.7M of revenue and $56.6M of EBITDA in Q1 against $641.6M and $140.1M in Q4. The more revealing framing is Q1 as a share of the full year. Q1 FY26 carried 23.0% of FY26 revenue and 19.8% of FY26 adjusted EBITDA. Q1 FY27 carries 22.1% of the guided revenue midpoint and only 16.9% of the guided EBITDA midpoint, so the year is more back-weighted on profit than the one it follows, even after a quarter that beat.

The quarter against management's own cadence

Consensus is the less interesting benchmark here. On the June call management laid out a precise cadence against its FY27 midpoints, and the Q1 implied by that cadence is the bar the company set for itself.

Revenue assessment. A record first quarter that beat the Street by 6% and management's own plan by 9% would normally settle the delivery question. It does not here, because the composition is poor. Three of the four largest contributors to the year-over-year change are an acquisition, a low-margin services category and a defense-systems line that is small relative to the franchise. The flagship went backwards: a $56.9M decline in Switchblade product revenue is roughly 12% of total quarterly sales, and it is attributed to order delays, which is the same mechanism that produced the 14% revenue miss two quarters ago. The order book answers this in part. Bookings of $683M, a 1.4x book-to-bill, trailing twelve-month bookings above $3B at 1.5x and record funded backlog of $1.5B say the demand is arriving even when the shipments do not. But demand that sits in backlog is a fiscal 2028 asset, and fiscal 2027 is the year being underwritten.

Margin assessment. The mix shift management needs is visibly starting. Firm-fixed-price revenue grew 16.8% to $349.4M and reached 72.7% of sales against 65.8%, while cost-plus fell 13.2% and time-and-materials fell 24.1%. Point-in-time recognition rose to 33% of revenue from 25%. Those are the mechanics of the margin story management described at the Investor Day, and they are working at the product line: adjusted product gross margin of 40% is the best first-quarter figure of the combined era. What offsets them is everything below gross profit. Adjusted SG&A at 18% of revenue sits four points above last year and two points above the top of the 14% to 16% full-year guide, so the second half must carry a meaningfully lower expense ratio for the year to land. Management attributes the increase to infrastructure, expanded business development and higher legal expense, which is consistent with a company integrating an acquisition while defending a securities suit. The service line is the weaker half of the story and management's explanation is incomplete. Service revenue rose $10.3M while service gross profit fell $3.2M. Management attributed that to volume loss and fixed-cost absorption in Cyber and Mission Solutions, but the filing shows the real driver is mix: $34.1M more customer-funded R&D at near-zero margin replacing $18.3M of higher-margin CMS work.

EPS assessment. At the GAAP line AV is still loss-making, at $(0.10) per share on a $(5.1)M net loss, and purchase accounting still dominates the bridge at $0.69 per share of intangible amortization. The adjusted $0.59 beat a $0.22 consensus by a wide margin, but the quality is thin for the reasons set out above, and the comparison flatters because last year's first quarter absorbed $17.4M of acquisition-bridge interest that no longer exists. The refinancing benefit is permanent and worth having. It is also fully in the run rate now, so it will not repeat as a growth driver. From here, adjusted EPS growth has to come from EBITDA, and management's own guidance says it will not: $3.02 to $3.34 brackets FY26's $3.31, because depreciation and cloud amortization rise from about $48M to about $87M at the guidance midpoint as the capacity build lands. The first quarter is consistent with that. Depreciation rose to $12.6M from $10.6M and cloud amortization to $1.9M from $0.9M, and both go higher as four new sites come online.

Segment Performance

Operating-group detail

AxS: the engine still works, but the flagship stalled

AxS grew 21.3% and produced $62.3M of segment adjusted EBITDA, which is more than the whole company reported because SCDE consumed $8.9M of it. It is the third time in four quarters that AxS has carried the entire profit of the business. Uncrewed Aircraft Systems is the standout, up 71.1% on the P550 ramp into the Army's Long-Range Reconnaissance program, JUMP 20-X and Puma, and management expects it to keep growing rather than fall back after what would ordinarily be a seasonal step down.

"So, the Uncrewed Aircraft Systems business performed exceptionally well in the first quarter, 71% year-over-year increase expected to continue with a significant growth this fiscal year excluded in our guidance. The strong awards that we got on P550, the increase in the JUMP 20-X, a strong commercial sales that we're seeing both domestically and internationally all led to that sustained growth, and we expect to continue to see growth in this business throughout the next few quarters." — Sean Woodward, EVP & CFO

Precision Strike and Defense Systems is the problem inside the good segment. Its 8.1% growth was presented on the call as loitering-munition led. The filing says the opposite: Switchblade product revenue fell $56.9M on order delays, more than ESAero's $41.8M and defense systems' $18.5M could offset, so the group's product revenue fell $6.8M and all of its growth came from services. Management's own characterization, that the group was "driven by our loitering munition family, along with our one-way attack system and counter-UAS RF Titan products", is hard to square with a $56.9M decline in the loitering-munition product line. Nobody on the call asked, because the disclosure was in a 10-Q filed later that evening.

AxS segment margin slipped 49bp to 18.0% even as revenue grew 21%. The filing attributes the muted flow-through to a $34.6M reduction in adjusted-EBITDA add-backs for depreciation, amortization, cloud amortization, stock compensation and acquisition expense, plus a mix shift toward services. Translated: as purchase accounting unwinds, less of the segment's cost base gets excluded, and the reported margin starts to reflect the real economics.

Assessment: the dependable-engine pillar holds, but it is now carrying a 71% growth line and a stalled flagship at the same time, and the Switchblade reversal has to arrive for the second-half plan to work. Management points to roughly 20 approved allied countries and an international Switchblade shift in the back half. That is the right answer if it converts to shipments, and it is the same answer the company gave two quarters ago.

SCDE: the award of the decade, and a bigger loss

SCDE revenue fell 20.6% and the segment swung from $3.8M of adjusted EBITDA to a loss of $8.9M, a $12.7M deterioration, and its worst margin since the acquisition closed. The revenue decline is explicable and was planned: the Space Force terminated SCAR in March, removing $32M of prior-year quarterly revenue, and Cyber and Mission Solutions lost $18.3M of service revenue on reduced contract scope. The loss is harder to dismiss, because the cost base did not come out with the revenue. Cost of sales fell $28.7M and SG&A fell $19.0M against a $34.9M revenue decline, but a $26.6M reduction in add-backs more than consumed the savings.

Set against that, the segment produced the most important award in the company's history. The Enduring High-Energy Laser contract, valued at close to $465M and announced in late August, is the first production contract the U.S. military has ever placed for a laser weapon. A first international LOCUST order as a direct commercial sale followed within days.

"As you recall, AV was awarded a landmark contract valued at nearly $465 million for the U.S. Army's Enduring High-Energy Laser or E-HEL program in late August. This award represents the first ever production contract for directed energy systems in U.S. military history." — Wahid Nawabi, Chairman, President & CEO

Management frames the margin recovery as a second-half event driven by volume and a contract-type shift, and expects the segment eventually to reach AxS-like economics.

"The LOCUST product line is going -- it is expected based on the contract wins that we have and the future ones that we expect to win, to have a very strong margin profile going towards the second half of this year and beyond... We expect the LOCUST product line and the segment 2 margin profile to eventually get to the same model of the segment 1 over the next couple of years." — Wahid Nawabi, Chairman, President & CEO

Assessment: the award resolves the question of whether anybody will pay for this technology at scale, which was the central doubt in the BlueHalo case. It does not resolve whether AV earns a return on it, and the Q1 loss moves that question in the wrong direction. Note also where the backlog sits. Of SCDE's book, $358M is funded and $1.2B is unfunded, so 89% of the company's unfunded backlog belongs to the segment that is losing money. The asymmetry is the whole SCDE debate in one line: enormous optionality, no current earnings, and a conversion schedule set by appropriations rather than by AV.

Key KPIs

Key Topics & Management Commentary

Overall Management Tone: The most confident call of our coverage period, and the least quantitative. Prepared remarks ran almost entirely on award announcements and capacity plans, with management reaching for the word "inflection" fifteen times across the hour, while the SCDE segment loss drew a single sentence and the loitering-munition decline went unmentioned. Analyst pushback was narrow and well-aimed, concentrated on why a quarter this far ahead of plan produced no change to the guide, and management's answers there were framework-level rather than specific. Tone has moved from the measured, remediation-focused posture of the June call to something closer to the promotional register of the first post-acquisition quarter a year ago.

1. The beat was reallocated, not banked

Management reaffirmed its headline FY27 numbers: revenue of $2.125B to $2.225B, adjusted EBITDA of $305M to $325M and adjusted EPS of $3.02 to $3.34. GAAP EPS guidance rose to $0.21 to $0.53 from $0.16 to $0.48. It also reaffirmed the cadence, holding the 45/55 first-half/second-half revenue split and the one-third/two-thirds EBITDA split. Those two decisions together are arithmetic, not sentiment. With Q1 revenue $40M above the implied figure and H1 unchanged at 45% of the midpoint, implied Q2 revenue falls to roughly $498M from the roughly $538M the June cadence implied. With Q1 EBITDA $18M above plan and H1 unchanged at one third of the midpoint, implied Q2 EBITDA falls to roughly $52M from roughly $70M.

The only cadence element that did move was the EPS split, from 25/75 to 30/70, which simply recognizes that Q1 already delivered more of the year's earnings than planned. On the reaffirmed midpoints, implied Q2 adjusted EPS is about $0.36 against about $0.60 previously implied.

"We're still holding to our 45-55 split. We got fantastic backlog. We've seen the back half of the year really been an increase in the overall volumes for our revenue. We did really good in Q1, we're able to deliver above our expectations. But the first half of the year, we're still tracking to the 45% and 55% in the back half of the year." — Sean Woodward, EVP & CFO

Assessment: there are two readings and they are not equally flattering. The charitable one is conservatism eight months before the year closes, with an unresolved appropriations process. The less charitable one is that the Q1 outperformance was a timing pull-forward out of Q2, in which case nothing happened to the year at all. Management's refusal to put any of the beat into the full-year number, held across three questions on the raise and the Q2 step-down, points toward the second.

2. The first production laser contract in U.S. military history

E-HEL is the most consequential thing in this print and arguably in the BlueHalo thesis. The U.S. Army placed a near-$465M production order for a high-energy laser, which no service has done before, and the FAA separately cleared the system as safe to operate in the national airspace. An international direct commercial sale followed within days, and management says the sequencing was deliberate: allies wanted the Army selection first, then a live demonstration.

"The second key criteria that was also for them to come to United States, go to the field test and push the 'I believe' button by shooting down drones themselves in the field. They did that. We demonstrated it. Our system worked while the competitive systems are not working, and therefore, they give us the award." — Wahid Nawabi, Chairman, President & CEO

On sizing, management expects LOCUST to become a franchise of more than $500M a year "in about a year or so", with the international market at least as large as the domestic one, and raised the possibility of non-defense critical-infrastructure applications two to three years out. The under-$10-per-shot cost argument against $1M to $5M interceptors is genuinely compelling economics.

Assessment: this validates the strategic logic of buying BlueHalo. It does not yet validate the price. A $500M revenue franchise inside a segment currently running a negative EBITDA margin is a promise about fiscal 2028 and beyond, and management put no margin number on it. The company has now been promising a SCDE profitability inflection for four consecutive quarters, and the segment's reported profit has gone $3.8M, then losses of $6.5M and $1.7M, then $1.4M, now a loss of $8.9M.

3. Titan, Golden Dome and the funded slice of a large ceiling

Titan MS won a sole-source $500M IDIQ supporting Joint Interagency Task Force 401's Domestic Shield program, with an initial $80M funded under the Golden Dome initiative. Titan sits inside AxS rather than SCDE, which is the detail that keeps getting lost in the BlueHalo debate: the acquired asset that is actually earning money today reports in the profitable segment, while the segment that bears the BlueHalo name carries the losses.

The structure also illustrates how little of AV's advertised contract capacity is money today. Management was explicit that reported unfunded backlog excludes IDIQ ceiling values, and listed the remaining headroom on the $990M Army Switchblade vehicle, the $874M UAS and counter-UAS foreign military sales vehicles and the $500M JIATF-401 vehicle as capacity beyond the $2.8B of reported backlog.

Assessment: the distinction between ceiling, unfunded backlog and funded backlog is where defense stories go wrong, and AV currently reports $1.5B funded and $1.4B unfunded, with further undisclosed headroom on three named IDIQ vehicles sitting outside both. Only the funded figure is appropriated money. The 23% sequential increase in the funded figure is the genuine progress in this quarter, and it is better evidence than any of the announced ceiling values.

4. Switchblade, the $56.9M nobody mentioned

The 10-Q filed later that evening discloses that Switchblade product revenue fell $56.9M year over year on order delays. Nothing in the prepared remarks or the Q&A refers to it. The call instead described Precision Strike as growing 8% and credited the loitering-munition family first among the drivers. On the direct question of what remained on the main Army vehicle, the answer was specific and smaller than most listeners would have expected.

"We have a couple of hundred million left on the current $990 million IDIQ under the current ceiling value remaining." — Sean Woodward, EVP & CFO

Management's forward framing is that domestic demand has carried Switchblade so far and the next leg is international, across close to 20 approved allied countries, weighted to the second half and beyond.

Assessment: this is the single most important disclosure of the quarter and it did not come from the company's own commentary. The decline is new: in the two preceding quarters the call described Switchblade sales as strong. The second-half plan requires it to reverse, and the mechanism named is an international pipeline with no announced contract behind it. We treat the $56.9M as a timing issue because the backlog and the approval list support that reading, while noting that the same reading was available two quarters ago and was borne out by the fourth-quarter rebound.

5. Four construction sites and a capex year

AV is building simultaneously in four places: a $100M Southern California innovation campus announced just after quarter-end, a 200,000 square-foot Salt Lake City loitering-munitions plant targeted for spring 2027, an Albuquerque expansion intended to be among the world's largest laser-weapon production facilities, and a newly purchased Huntsville site for the Freedom Eagle-1 interceptor. Capex plus capitalized software of $49.5M in Q1 is 10.3% of revenue, below the 12% to 14% full-year guide, which means the spending accelerates from here. Management argues the capacity itself wins the awards.

"There is a direct correlation and link between us investing in showing our customers that we can deliver and producing and delivering on time and a reliable product to the customer and getting a lion's share of the business. Many people can claim that they have it, or they can do it. But unless they demonstrate, it's not the same thing." — Wahid Nawabi, Chairman, President & CEO

Assessment: the industrial logic is sound and the P550 and Titan award histories support it. The shareholder question is the return, and that is not yet answerable. At 13% of the revenue midpoint, capital spending runs near $283M against guided adjusted EBITDA of $315M, so roughly 90 cents of every dollar of operating profit goes into plant. The depreciation that follows is precisely why adjusted EPS is guided flat. The Southern California consolidation is the one project with a near-term identified payback, through lower lease expense across the facilities it replaces.

6. Freedom Eagle-1 and the layered counter-UAS architecture

Management laid out the counter-UAS portfolio as three layers: Titan jammers against radio-frequency-controlled drones, LOCUST lasers where jamming fails, and the FE-1 kinetic interceptor as last resort. The Army asked AV to accelerate FE-1 under the Long-Range Kinetic Interceptor program and Congress appropriated additional money to do so. Management expects to deliver 60 to 80 systems over the next 12 to 18 months of test and certification before low-rate and then full-rate production, which it sizes as a $1B franchise and places roughly 12 months out.

Assessment: the layered pitch is strategically coherent and is the reason AV can claim a differentiated counter-UAS position rather than a single product. For the FY27 model it contributes test-article revenue and capital spending, not profit. The useful detail is the congressional plus-up, which is the clearest evidence in the quarter that AV's programs have political support independent of the normal budget cycle.

7. Backlog quality and the 86% visibility claim

Revenue visibility to the midpoint reached 86%, against 69% disclosed at the June call. Funded backlog of $1.5B is up 37% year over year and 23% sequentially, with total funded and unfunded backlog at roughly $2.8B. Bookings of $683M produced a 1.4x book-to-bill, and the trailing twelve-month figure exceeded $3B at 1.5x. Management also confirmed the recent Titan and LOCUST awards are already inside the FY27 outlook rather than incremental to it.

Assessment: this is the strongest part of the print and it materially lowers the probability of a revenue-driven miss. It is worth being precise about what it does not cover. The remaining 14% of the midpoint is roughly $300M that still has to be booked and shipped inside the year, and visibility is a statement about revenue, not margin. The second-half problem in this plan has never been whether the sales arrive. It is whether they arrive at 17.6% EBITDA margin.

8. The budget, the continuing resolution and an election

Management named the timing of the government fiscal 2027 appropriation as the main external risk and said its guidance assumes a short continuing resolution followed by an approved defense budget around December, unchanged from the June assumption.

"The biggest, what I call question mark is how fast can Congress approve the next fiscal year's budget. It's really not that relevant, whether it's $1.3 billion or $1.5 trillion, I'm sorry, or $1.8 trillion, whatever the number ends up being, as long as the budget gets approved and most likely it will be not less than this government fiscal year." — Wahid Nawabi, Chairman, President & CEO

Assessment: the assumption is reasonable and explicitly embedded, which is better practice than leaving it implicit. The exposure is asymmetric, though. A December budget is already in the plan, so there is no upside from it arriving on time, while a slip past December lands squarely on the second half that carries two-thirds of the year's profit. Management acknowledged that if the delay extends, "obviously the risk profile increases".

9. International expansion through local industrial partnerships

Non-U.S. government revenue grew 57.9% to $93.7M and reached 19.5% of sales, while U.S. government revenue declined 2.2%. Behind that, AV announced an AV Eagle joint venture in Greece in August and has existing presence or partnerships in the United Kingdom, Germany, Turkey and Taiwan, with more expected across Europe, the Middle East and Asia Pacific. Management was candid that this is the price of access: allied governments want local content, local assembly or both.

Assessment: the mix shift is real and it is the growth that is actually showing up this year. Two cautions. Local industrial participation structurally dilutes margin relative to export from a U.S. plant, and management has not quantified that effect. And on Greece specifically, management confirmed the recently signed multi-billion missile-defense package does not currently include LOCUST, which is a useful corrective to the assumption that every allied air-defense program is an AV opportunity.

10. Two material weaknesses, still open, plus a securities suit

The 10-Q states that disclosure controls and procedures were not effective as of August 1, 2026, on account of two material weaknesses. The first, which our June note discussed, concerns the design of controls over the goodwill impairment analysis that produced the Q3 restatement. The second is new to our coverage and was disclosed in the FY26 annual report: BlueHalo did not design or maintain effective information-technology general controls, specifically user-access controls ensuring segregation of duties and restricting privileged access, so the automated and IT-dependent manual controls relying on those systems were deemed ineffective. Remediation of both is in progress, and management states plainly that the remedial controls must operate for a sufficient period before any conclusion can be drawn.

Separately, a securities class action was filed on May 26, 2026 in the Eastern District of Virginia, naming the company, the chief executive, the former chief financial officer and the president of the SCDE segment, and alleging misleading statements about the SCAR program over a class period running from June 25, 2025 to March 10, 2026. A second class action on the same allegations followed in the District of Delaware on July 17, and two derivative actions were filed in late July. Higher legal expense was one of the items management cited in the SG&A increase.

Assessment: neither item is new company news, but both are new to this coverage and both cut against paying a premium multiple. A company whose disclosure controls are formally ineffective across two separate domains, one of them the acquired entity's entire IT control environment, is a company whose reported numbers carry a wider confidence interval than a peer's. That is a valuation input, not a footnote. We hold the base multiple rather than expanding it partly for this reason.

11. Tariffs and the supply chain as a stated advantage

Asked about new tariffs on drone components, management said more than 98% of AV's supply base is domestic, with the remainder in Canada, Germany and Israel, and framed the measures as a net positive because competitors must adjust and AV does not.

Assessment: plausible and consistent with AV's long-standing International Traffic in Arms Regulations posture, and a genuine competitive asset against the low-cost drone entrants that have taken share in the small-UAS market. It is also unverifiable from the outside, and the 98% figure is management's. We do not model a tariff benefit, but we do not model a cost either.

Guidance & Outlook

The implied ramp, before and after

Applying the reaffirmed splits to the unchanged midpoints of $2,175M revenue, $315M adjusted EBITDA and $3.18 adjusted EPS gives the following. The June column is the cadence as management described it on the fourth-quarter call; the September column reflects Q1 actuals with the same splits held.

Implied Q2 figures are our derivation from the reaffirmed splits, not company guidance. Management corroborated both directions on the call: it declined to move the 45/55 revenue split when the roughly $40M step-down was put to it directly, and it confirmed that Q2 adjusted EBITDA steps down sequentially even as revenue rises, citing a weaker sales mix and a planned increase in internally funded research.

Implied second-half requirement. H2 must produce $1,196M of revenue at a 17.6% adjusted EBITDA margin, against the 10.7% the first half implies and the 11.1% Q1 delivered. That is a 690bp step inside one fiscal year. The reassuring precedent is that AV did exactly this twelve months ago: FY26's second half delivered $1,049.6M of revenue at a 17.6% margin, the same figure to the decimal. The unsettling detail is how. FY26's Q3 ran at 10.9% and its Q4 at 21.8%, so the entire second-half margin was one quarter. If FY27 repeats that distribution, the fourth quarter again carries the year, which is the structure that drove our downgrade two quarters ago.

Street position. Consensus for FY27 adjusted EBITDA, available from a single provider, sat near $318M entering the print, above the $315M guidance midpoint and inside the upper half of the range. A reaffirmation therefore does not lift the Street number; it leaves consensus modestly ahead of the company. That is the opposite of the setup a quarter this far ahead of plan would normally create, and it is the clearest signal that management is holding capacity in reserve rather than seeing upside it is unwilling to name.

Guidance style. Over the preceding five quarters AV revised FY26 guidance three times, raising adjusted EPS once and cutting it twice, then beat the reduced target. The reaffirmation here is consistent with a management team that has learned to set a floor it can clear rather than a target it might miss, which is the right adjustment after that record. The cost of the adjustment is that guidance now carries less information. When the plan does not move on a 53% EBITDA beat against the internal cadence, the guide stops being a forecast and becomes a commitment, and investors have to model the business themselves.

Analyst Q&A Highlights

Why a quarter this far ahead of plan produced no raise

The dominant line of questioning on the call. With revenue 9% and adjusted EBITDA 53% above the figures management's own cadence implied, the obvious question was what had gone the other way. The answer named one thing, appropriations timing, and otherwise argued that one quarter is too early. Management volunteered that it had asked itself the same question.

Q: "And was there any deviation on the timing that you expected on these awards? Was anything slower? Or just kind of wondering -- the question we're getting is why you didn't raise. So just hoping to couch on maybe some of the things that didn't go your way if things are just happening a little bit slower than you thought?"
— Jonathan Siegmann, Stifel

A: "So Jon, that's a great question. We've asked ourselves that question several times, right? We believe that we've got a lot of work coming our way. There is one thing that's really uncertain about the market today, which is the timing of the fiscal year government fiscal year 2027 budgets. We have an election year, a lot of elections and uncertainty within Congress. That by itself represents a significant potential risk. We don't believe that's going to affect our current guidance, and it's only our first quarter. We just came out of the gate on our first quarter."
— Wahid Nawabi, Chairman, President & CEO

Assessment: the answer is internally inconsistent. If appropriations timing is "a significant potential risk" that nonetheless does not affect current guidance, it is not the reason the guide did not move. The honest reading is that the quarter pulled revenue forward and management is not willing to say so. That is a defensible posture after two guidance cuts last year, but it means investors must treat the reaffirmation as a floor rather than as a forecast.

The arithmetic of an unchanged first-half split

One analyst did the subtraction out loud. Holding 45% of annual revenue in the first half while Q1 came in $40M high mechanically takes $40M out of the implied second quarter relative to what the prior call described. The response did not dispute the arithmetic and did not move the split.

Q: "Obviously, you guys had a solid first quarter results here on revenue. But with you still expecting 45% of revenue to come in the first half that implies about a $40 million step down in revenue in 2Q relative to what you guys said on the last call about the 1Q, you split if we just take things at the midpoint. So just kind of wanted to unpack that and if there's any particular reason for that."
— Cashen Keeler, BNP Paribas

A: "We're still holding to our 45-55 split. We got fantastic backlog. We've seen the back half of the year really been an increase in the overall volumes for our revenue. We did really good in Q1, we're able to deliver above our expectations. But the first half of the year, we're still tracking to the 45% and 55% in the back half of the year. Well supported by our visibility at 86%, and overall increased volumes in Q3 and Q4."
— Sean Woodward, EVP & CFO

Assessment: confirmation that the beat was absorbed rather than banked, delivered without hedging. The 86% visibility reference is the company's best counter-argument and a genuinely good one, but it supports the second half, not the second quarter. Our implied Q2 revenue of roughly $498M is therefore management-corroborated, not merely derived.

Why second-quarter profit falls while second-quarter revenue rises

The follow-up that mattered more than the revenue version. A higher revenue quarter producing lower profit requires an explanation, and the one given was mix plus a deliberate increase in internally funded research.

Q: "And then just back to 2Q kind of guide, I appreciate it's early in the year and there's still a lot of budget unknowns. But is there anything specific in 2Q that steps down EBITDA, even while revenue increases?"
— Gavin Parsons, UBS

A: "So Q2, the way we laid this out with our revenue profile at the 45-55, the back half of the year being a more favorable volume and improved sales mix. That was driving the EBITDA in the second half of the year. First half of the year, we delivered really strong in Q1. And in Q2, we see a little bit of a step down even though the volumes of higher the overall sales mix is slightly below, and then our increased IRAD is expected to tick up in Q2."
— Sean Woodward, EVP & CFO

Assessment: an explicit confirmation of a sequential EBITDA decline, and the research point is credible given Q1 R&D ran at 5.0% of revenue against a 7% to 9% full-year guide. Roughly $10M to $20M of R&D has to come back into the second and later quarters, so part of the Q1 margin beat was timing of spend rather than operating leverage. That reframes the 53% EBITDA beat materially.

Headroom remaining on the main Switchblade vehicle

A question about what capacity is left in the large loitering-munition indefinite-delivery vehicles drew the most specific number of the call, and a smaller one than the headline ceiling implies.

Q: "Wahid, could you give us an update on kind of like you won some very large IDIQ contracts supporting the Switchblade production. Where do we stand on what's left in those vehicles? And what -- could you give us an update there?"
— Peter Arment, Baird

A: "Yes, Peter. We have a couple of hundred million left on the current $990 million IDIQ under the current ceiling value remaining."
— Sean Woodward, EVP & CFO

Assessment: roughly 80% of the flagship domestic vehicle has been consumed. Management's answer elsewhere was that domestic demand "really has been the dominant factor in growth so far, and it's going to shift a little bit more towards international". Read alongside the undisclosed $56.9M decline in Switchblade product revenue, that is a franchise in transition between funding sources, not a franchise with a full order book. The international pipeline across roughly 20 approved countries is the replacement and none of it is contracted yet.

Whether the uncrewed-aircraft surge is sustainable

Uncrewed Aircraft Systems grew 71% and showed almost no sequential decline where the fiscal calendar usually produces one, which prompted a direct question about pull-forward.

Q: "Just wanted to ask, in the uncrewed systems business, we saw some strong results and pretty much no change relative to the fourth quarter, even though there's usually a meaningful seasonal step down. Anything kind of pulled forward there? Or any reason we wouldn't expect sales there to grow off of the Q1 level?"
— Seth Seifman, JPMorgan

A: "Seth, yes. So, the Uncrewed Aircraft Systems business performed exceptionally well in the first quarter, 71% year-over-year increase expected to continue with a significant growth this fiscal year excluded in our guidance. The strong awards that we got on P550, the increase in the JUMP 20-X, a strong commercial sales that we're seeing both domestically and internationally all led to that sustained growth, and we expect to continue to see growth in this business throughout the next few quarters."
— Sean Woodward, EVP & CFO

Assessment: a clean denial of pull-forward and a forward commitment to sequential growth, which is the strongest single forward statement on the call. It is also checkable next quarter, which makes it the most useful one. The supporting detail is credible: management expects to deliver almost all of the $117M Long-Range Reconnaissance award within this fiscal year, which places a known revenue block in the second half.

How long the service-margin drag persists

Adjusted service gross margin fell to 8% from 13%, and the question was whether this is a volume problem that fixes itself or something structural.

Q: "Sean, maybe I'll start with you. I understand -- I appreciate the color around the gross margin on the services business. Is that really just going to be a function, or I guess how long is that going to stick with us in terms of that being a bit of a drag? Is it really just until the revenues come back to kind of cover the headcount, or are there other kind of dynamics maybe over the next couple of quarters that you guys can shift things around, so that's not as much of a factor."
— Trevor Walsh, Citizens

A: "Yes, Trevor. Great question. Yes. So the services margins, we did see a downtick in quarter 1 compared to last year, mainly driven by the volume and the reduction in the overall business volume of our services revenue, with the start of the contract being T&M and some of that revenue not being able to absorb the fixed costs, we saw the reduction in the gross margin... Services margin isn't really where we're focused on growing overall margins, really the transition to products and commercialization of our products is really where the expansion of our overall EBITDA is going to come from."
— Sean Woodward, EVP & CFO

Assessment: the answer is directionally honest about priorities but factually incomplete about causation. Service revenue rose $10.3M in the quarter; it did not decline. What fell was service profit, because $34.1M of near-zero-margin customer-funded research displaced higher-margin mission work. Framing that as a volume and absorption problem implies it self-corrects with growth, when the filing suggests it corrects only with a change in mix. The de-prioritization is strategically defensible, since services are a third of revenue and a small fraction of profit, but it is one more component of the second-half margin step that has no visible mechanism yet.

Free cash flow and whether the continuing resolution is in the plan

The cash question our prior note flagged as unanswered was asked again, together with whether the budget assumption is explicit in guidance. The second half of the answer was precise; the first half still was not.

Q: "Wondering if you could comment on the major drivers of cash outperformance in the quarter. What changed in your view and how you see receivables growing or shrinking over the coming quarters? And then just is the CR explicitly considered in your full year guidance for negative free cash flow?"
— Clarke Jeffries, Piper Sandler

A: "We're anticipating managing the cash from a free cash flow perspective for the full year being slightly negative, driven mainly from the CapEx, managed working capital favorable growth in EBITDA and net income, but really the CapEx is going to drive us to the current year increase in CapEx, driving the free cash flow is negative. We don't anticipate that carrying into next year, we expect to see our capital levels return to more normalized level... Regarding your second question on the CR. So that is factored into our guidance... a short-term CR followed by an approved defense budget, that's what we're expecting to happen in the December time frame."
— Sean Woodward, EVP & CFO

Assessment: two new pieces of information and one persistent gap. New: the word "slightly" now qualifies the negative free-cash-flow guidance, and management expects capital intensity to normalize in fiscal 2028. Also new and useful: the December budget assumption is stated as embedded rather than implied. The gap is unchanged. There is still no range, and the third condition we set in June for an upgrade was a quantified path through the cash-use year. It remains unmet two quarters running.

Whether the laser awards convert into segment profit

The first question of the call went straight to the issue that decides the BlueHalo thesis: whether landmark orders translate into margin, and when.

Q: "I was just wondering, how should we think about LOCUST profitability? And what could the recent awards mean for SCDE with margins over the longer term?"
— Edward Morgan, BTIG

A: "As you know, we're at an inflection point in the segment 2 profitability profile and products that are being commercialized. The LOCUST product line is going -- it is expected based on the contract wins that we have and the future ones that we expect to win, to have a very strong margin profile going towards the second half of this year and beyond... It's because a lot of the LOCUST and a few other products in that segment is going to have higher volumes as firm fixed price contracts take over and the margin profile improves significantly."
— Wahid Nawabi, Chairman, President & CEO

Assessment: the mechanism described, volume plus a shift to firm-fixed-price contracting, is the right one and is already visible at the company level, where firm-fixed-price revenue reached 72.7% of sales from 65.8%. What is missing is any number. The segment lost $8.9M this quarter and management has now forecast a profitability inflection in four consecutive quarters without attaching a margin target or a date beyond "the second half". Until a number appears, the most defensible modelling choice is to carry SCDE near breakeven and let AxS underwrite the valuation.

What They're NOT Saying

1. A $56.9M decline in Switchblade product revenue: disclosed in the 10-Q that evening, absent from both the prepared remarks and the Q&A. The call attributed Precision Strike growth to the loitering-munition family. Roughly 12% of quarterly revenue moved in the opposite direction from the narrative, and the only reason an investor would know is the filing.
2. An organic growth figure: the same omission as last quarter. ESAero contributed $41.8M of revenue and management again declined to separate acquired from underlying growth. On our calculation the business shrank roughly 3.5% excluding that contribution, and nothing management disclosed contradicts or confirms it.
3. A quantified free-cash-flow range: now the second consecutive quarter with direction but no magnitude. "Slightly negative" is an improvement on "negative" and still not a number an investor can underwrite, in a year where capital spending runs near 90% of guided operating profit.
4. Who the $4.2M bad-debt reserve relates to: management called it unexpected and non-recurring but named neither the counterparty nor the program. The filing shows bad-debt expense up $4.4M year over year and the allowance for credit losses rising from $2.0M at April 30 to $6.5M at August 1. A single receivable of that size inside a defense contractor usually implies an international or commercial customer, which is the fastest-growing part of the revenue mix.
5. Any SCDE margin target: four quarters of inflection language and no number, no date and no bridge from a negative 6.6% margin to the AxS-like model management says is achievable "over the next couple of years". The segment holds 89% of the company's unfunded backlog, so this is not a small corner of the business.
6. The second material weakness, and the securities suit: neither came up on the call. The BlueHalo information-technology control failure covers the acquired entity's user-access and segregation-of-duties environment, and disclosure controls are formally ineffective as a result. The SCAR class action names the chief executive and the segment president. Management discussed remediation in June when the goodwill weakness was the only one in view; this quarter it discussed neither.
7. What the Greece joint venture and similar structures cost in margin: management confirmed that allied access increasingly requires local content, local assembly or both, across Greece, the United Kingdom, Germany, Turkey and Taiwan. Non-U.S. government revenue grew 57.9% and is the engine of this year's growth. No one has quantified the margin differential between an export sale and a locally assembled one.

Market Reaction

• Pre-print setup: AVAV closed at $140.80 on September 9, down 41.8% year to date, 25.6% over the trailing 30 days and 39.0% over the trailing 12 months. The pre-print 52-week closing range was $136.68 to $409.83, so the stock entered the print roughly 3% above its 52-week low and 66% below its high. The S&P 500 had entered the print up 11.6% year to date.
• Reaction session, September 10: shares opened at $146.77, a 4.2% gap, traded between $142.50 and $159.24, and closed at $147.07, up 4.5% or $6.27. The intraday high was 13.1% above the pre-print close.
• Volume: 8.8M shares against a 1.3M 30-day average, or 6.9x normal activity.
• Market comparison: the S&P 500 fell 0.6% in the reaction session, so the relative move was roughly 5 points.

The setup explains more of this reaction than the print does. The stock had lost a quarter of its value in the 30 days into the print, and most of that drawdown came in the second half of August, not from the July events that preceded it. Management held an investor day on July 8 and set fiscal 2030 targets of $3.5B to $4.0B of revenue and an 18% to 20% adjusted EBITDA margin. Shares fell 2.9% that day and a further 5.9% the next, when a sell-side downgrade argued that those targets require an acceleration in fiscal 2028 through 2030 that flat defense budgets and capacity-expansion risk make hard to underwrite. The stock then more than recovered, closing at $189.15 on August 10, the start of the 30-day window. Three single-day declines of 6.1%, 7.5% and 7.5% followed in the second half of August, and the shares fell a further 5.4% in the session before the release.

Against that, a 4.5% gain on a 6% revenue beat, a 53% EBITDA beat against management's own cadence and a record funded backlog is a muted response, and the shape of the session says why. The gain peaked at 13.1% intraday and gave back roughly two-thirds of it before the close. That is the signature of an initial headline read followed by a closer one. The headline is a record first quarter and the first production laser contract in U.S. military history. The closer read is a reaffirmed guide that absorbs the entire beat, a segment that swung to a loss, and an adjusted EBITDA line that fell year over year. The buyers who bid the stock to $159.24 were responding to the first; the sellers who took it back to $147.07 had worked through the second.

Volume at 6.9x the 30-day average is high even for an earnings session and is consistent with genuine repositioning rather than a drift higher on thin trade. We would not read the close as a verdict on the quarter so much as a market still unwilling to pay the previous multiple for a company whose profitability inflection keeps being scheduled for a later period.

Street Perspective

Debate: does a 53% beat against the internal plan mean anything if the plan does not change?

Bull view: the bull case on the Street is that management has simply learned to guide conservatively after two cuts last year, and that a company running $40M of revenue and $18M of EBITDA ahead of its own cadence one quarter into the year is far more likely to finish above the midpoint than below it. On this view the reaffirmation is a floor and the second half is where the raise comes from.

Bear view: the bear camp argues that a quarter which changes nothing about the full year is worth nothing to a twelve-month investor, and that the refusal to raise is information rather than caution. If the Q1 upside were durable, some of it would have reached the annual number; instead the implied second quarter went down by roughly the amount the first went up.

Our take: the bears have the better of this one on the evidence available today, but only just. The decisive fact is not the reaffirmation itself but what the quarter was made of. A beat built on an acquisition, low-margin funded research and a 71% uncrewed-aircraft quarter, while the flagship loitering-munition line fell $56.9M, is not the kind of beat that gets added to a full-year number. We will revisit this if the second quarter lands near the implied $498M rather than below it.

Debate: has the directed-energy award changed what BlueHalo is worth?

Bull view: the bull argument is that a near-$465M production contract, the first the U.S. military has ever awarded for a laser weapon, plus an immediate international follow-on and FAA clearance for domestic airspace, converts directed energy from an option into a business. On this reading the segment is a $500M-plus franchise within two years and the acquisition premium is retrospectively justified.

Bear view: the skeptics note that the segment carrying this franchise lost $8.9M of EBITDA this quarter on a 20.6% revenue decline, holds 89% of the company's unfunded backlog and none of its profit, and has had a promised margin inflection in each of the last four quarters without one arriving. Orders are not earnings, and the write-down of this asset twelve months after purchase is still recent.

Our take: both are right about different questions. The award resolves demand and resolves it emphatically, which was the larger of the two uncertainties and is the single best piece of news in this print. It does not resolve returns, and the quarter made the returns question worse. We give the pillar credit for the order and leave its status unchanged until a segment margin number appears.

Debate: is the de-rating an opportunity or a correct repricing of the 2030 plan?

Bull view: the stock has fallen 39% year to date and trades at roughly 24x this year's guided EBITDA against 27x in June, while funded backlog grew 23% in a single quarter and revenue visibility improved 17 points. On the bull view the market de-rated the long-term targets and has not re-rated for the near-term delivery that followed.

Bear view: the bear camp contends the de-rating is the market correctly marking a plan that requires roughly 20% annual revenue growth and 450bp of margin expansion across fiscal 2028 to 2030, immediately after a year guided to 10% growth and flat earnings per share. At 46x adjusted earnings with negative free cash flow, a GAAP net loss and two unremediated material weaknesses, the shares are not cheap in any absolute sense.

Our take: the bears have the stronger argument about the multiple and the bulls the stronger argument about the direction. Our base value is unchanged at $174 and the price has fallen, so the apparent return has improved substantially. What has not improved is the width of the distribution around it, and the quarter did not narrow the one variable that matters most, which is whether the second half converts at 17.6%.

Our Estimates & Valuation

Why nothing in the model moved. Management reaffirmed revenue, adjusted EBITDA and adjusted EPS guidance and we adopt the midpoints, as we did in June. The quarter redistributed earnings within the first half rather than adding to the year, so the annual estimates are unchanged by construction. The two genuinely new inputs are the balance sheet, where net debt rose to $72.5M from $34.1M as Q1 consumed cash, and the backlog, where funded orders grew 23% sequentially and visibility rose to 86% of the midpoint from 69%. The first is already inside the forward net-debt assumption; the second raises our confidence in the revenue line without changing its level.

Valuation method. We value FY27 adjusted EBITDA at the end of a consistent twelve-month horizon, the same framework used in June. At $147.07, 51M valuation shares and $72.5M of current net debt imply $7.57B of enterprise value, or 24.0x FY27 EBITDA and 46x adjusted EPS. Net debt is the $747.5M of zero-coupon convertible principal less $675.0M of cash and investments; no dividend is assumed.

We hold the 28.5x base multiple rather than expanding it. The case for a higher number is real: the E-HEL production award is a first-of-its-kind contract, funded backlog set a record, and firm-fixed-price mix moved 690bp in the right direction. The case against is equally concrete. Adjusted EBITDA fell year over year, the segment that would justify a premium lost money, the flagship product line fell $56.9M, and disclosure controls remain formally ineffective across two separate material weaknesses. Those cancel. The entire improvement in expected return therefore comes from a price that fell 10.9% since our last note while the base value stayed at $174.

The base calculation is (28.5 × $315M − $100M) ÷ 51M = $174.07. Scenario inputs are carried over unchanged from June so the comparison is clean. Holding the bear case constant is now conservative in one respect and not in another. The $2.00B bear revenue looks less likely than it did three months ago, since 86% of the midpoint is already visible and reaching $2.00B would require the second half to miss its implied level by 15%. But the bear value is driven by the 22.0x multiple and the $200M of forward net debt rather than by the revenue line, and neither of those has become less plausible. A multiple of 22x sits only modestly below the 23.0x implied by the pre-print close.

The cash assumption is the weakest link. Our $(65)M free-cash-flow estimate requires $218M of operating cash flow for the year. Q1 produced $13.5M, so $204M has to arrive across the remaining three quarters against roughly $233M of residual capital spending. That implies converting about 78% of the remaining $262M of guided EBITDA into operating cash. The combined company has never done that: FY26 produced negative $78.4M of operating cash flow on $286.1M of adjusted EBITDA, and Q1 converted at 25%. Inventories rose $97.9M in the quarter and unbilled receivables rose $67.4M, both deliberate, both cash. If conversion lands closer to 50%, free cash flow is nearer $(139)M and forward net debt nearer $174M, which costs about $1.45 per share of base value and, more importantly, moves the bear case closer to its $200M assumption. This is the single estimate we would most like to replace with a company number.

Return judgment. A base case offering 18.4% against our 7% nominal twelve-month assumption for the broad market would normally support an Outperform, and the distribution is no longer skewed against us: the bull outcome is worth more than two and a half times the bear in absolute terms. What holds the rating is that the base case now depends on three things happening together in the same six months. The second half must convert at 17.6% EBITDA margin, Switchblade must reverse a $56.9M decline, and cash conversion must run at roughly 78% after a year of negative conversion. Each is individually plausible. None has started, and the quarter just reported tested none of them.

Thesis Scorecard Post-Earnings

Overall: the thesis is unchanged in substance and better priced. The order book moved decisively in our favor and the directed-energy award removes the largest single doubt about the acquisition's strategic logic. Nothing in the quarter advanced the profitability question, and two risk disclosures moved against us. The standing arrangement of pillars survives intact, which is itself informative after five quarters in which it has been rearranged almost every time.

Against the conditions we set in June. We said an upgrade to Outperform required repeated delivery against the FY27 cadence, funded counter-UAS production awards and a quantified path through the negative cash-flow year, with the price still offering sufficient return. The second condition is met emphatically. The fourth is met. The first is partially met, by one quarter against a four-quarter cadence that back-loads two-thirds of the profit, and weakened by the fact that the delivery was inorganic. The third is not met at all, for the second consecutive quarter.

What would change the view: a second quarter landing at or above the implied $498M of revenue and $52M of EBITDA without further reallocation, a quantified FY27 free-cash-flow range, or SCDE returning to positive segment EBITDA would each move us toward Outperform, and any two together would get us there at this price. In the other direction, a reduction to the FY27 guide, a second quarter below the implied figures, a further deterioration in SCDE margin, or evidence that the Switchblade order delays are competitive rather than budgetary would reopen the Underperform case.

Action: Maintain Hold. The shares are closer to an upgrade than at any point in our coverage, and we would rather be early on the second data point than on the first. Buy the second quarter if it holds the line without another reallocation.